Search

Lonza Group AG

Затворен

536 0.49

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

534.2

Максимум

546

Ключови измерители

By Trading Economics

Приходи

244M

Продажби

-582M

3.1B

P/E

Средно за сектора

26.67

EPS

4.61

Марж на печалбата

6.705

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-144M

40B

Предишно отваряне

535.51

Предишно затваряне

536

Настроения в новините

By Acuity

50%

50%

Lonza Group AG Графика

Свързани новини

25.07.2024 г., 08:07 ч. UTC

Печалби
Значими двигатели на пазара

Lonza Shares Rise After Company Backs Outlook

25.07.2024 г., 05:31 ч. UTC

Печалби

Lonza Backs View Despite Earnings Slip

20.03.2024 г., 08:45 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Lonza Shares Jump on U.S. Manufacturing Facility Buy From Roche

20.03.2024 г., 06:59 ч. UTC

Придобивния, сливания и поглъщания

Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Billion

25.07.2024 г., 07:49 ч. UTC

Пазарно говорене
Печалби

Lonza Shows Prospect of a Potential Guidance Raise -- Market Talk

25.07.2024 г., 04:59 ч. UTC

Печалби

Lonza Backs 2024 View

25.07.2024 г., 04:58 ч. UTC

Печалби

Lonza 1H Core Ebitda Fell 3.1%

25.07.2024 г., 04:58 ч. UTC

Печалби

Lonza 1H Core Ebitda CHF893M

25.07.2024 г., 04:58 ч. UTC

Печалби

Lonza 1H Ebitda Margin 28%

25.07.2024 г., 04:57 ч. UTC

Печалби

Lonza 1H EBITDA CHF862M

25.07.2024 г., 04:57 ч. UTC

Печалби

Lonza 1H Sales Fell 0.7%

25.07.2024 г., 04:56 ч. UTC

Печалби

Lonza 1H Sales CHF3.06B

14.05.2024 г., 05:02 ч. UTC

Печалби

Lonza Key Growth Projects Progressing in Line With Plan

14.05.2024 г., 05:02 ч. UTC

Печалби

Lonza Expects Solid 2H Sales

14.05.2024 г., 05:01 ч. UTC

Печалби

Lonza Had Softer 1Q Performance

14.05.2024 г., 05:01 ч. UTC

Печалби

Lonza Sees Flat CER Sales Growth

14.05.2024 г., 05:01 ч. UTC

Печалби

Lonza Sees Core Ebitda Margin in High Twenties

14.05.2024 г., 05:01 ч. UTC

Печалби

Lonza Backs 2024 View

2.04.2024 г., 08:22 ч. UTC

Пазарно говорене

Lonza's Next CEO Brings Strong Standing Among Investors -- Market Talk

2.04.2024 г., 08:22 ч. UTC

Пазарно говорене

Siegfried Holding Unlikely to Change Strategy Despite CEO Departure -- Market Talk

2.04.2024 г., 07:37 ч. UTC

Пазарно говорене

Lonza CEO Appointment to Be Well Received -- Market Talk

23.03.2024 г., 13:00 ч. UTC

Топ новини

U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies -- Heard on the Street -- WSJ

20.03.2024 г., 11:30 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Intel, Boeing, Chipotle, Micron -- WSJ

20.03.2024 г., 09:41 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Intel, Chipotle, Micron -- WSJ

20.03.2024 г., 09:26 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Lonza's U.S. Manufacturing Facility Buy Is a Positive -- Market Talk

20.03.2024 г., 06:44 ч. UTC

Придобивния, сливания и поглъщания

Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Bln

20.03.2024 г., 06:10 ч. UTC

Придобивния, сливания и поглъщания

Lonza: Transaction Is Expected to Close in 2H

20.03.2024 г., 06:09 ч. UTC

Придобивния, сливания и поглъщания

Lonza: Some 750 Genentech Employees at the Site Will Be Offered Employment

20.03.2024 г., 06:09 ч. UTC

Придобивния, сливания и поглъщания

Lonza: Facility Is One of the Largest Biologics Manufacturing Sites in the World by Volume

20.03.2024 г., 06:08 ч. UTC

Придобивния, сливания и поглъщания

Lonza to Acquire Site for $1.2B in Cash

Lonza Group AG Прогноза

Консенсусна оценка

By TipRanks

Купи

7 ratings

3

Купи

4

Задържане

0

Продай

Настроение

By Acuity

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Lonza Group AG

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.